APOTHEEK GLORIEUX
0420.109.869 · rovalta.com · 23/09/2026
APOTHEEK GLORIEUX
Overview
What does APOTHEEK GLORIEUX do?
APOTHEEK GLORIEUX is a Private limited company incorporated in 1980. Its registered office is in Zwevegem. It employs on average 2,6 ETP workers (FTE).
8550 Zwevegem · FlandreSee on map
Joint committees (1)
- 313
Trend over 20 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||||||||||||||||||||||||||||
| Gross margin | 568,2 k € | -4.1% | 592,7 k € | +6.7% | 555,6 k € | -2.8% | 571,7 k € | +4.3% | 547,9 k € | -9.0% | 602 k € | +36.4% | 441,4 k € | -4.5% | 462,2 k € | -1.4% | 468,8 k € | -12.0% | 532,6 k € | +17.3% | 454,1 k € | +1.8% | 446 k € | +36.0% | 327,8 k € | +8.5% | 302,2 k € | +72.2% | 175,5 k € | +27.6% | 137,5 k € | -45.6% | 252,9 k € | -6.9% | 271,5 k € | -0.7% | 273,3 k € | +12.6% | 242,8 k € |
| EBITDA | 392,1 k € | -12.0% | 445,6 k € | +18.7% | 375,6 k € | -5.4% | 396,9 k € | +1.7% | 390,1 k € | -7.5% | 421,7 k € | +65.7% | 254,5 k € | -20.7% | 321 k € | +16.4% | 275,8 k € | -10.1% | 306,8 k € | +29.3% | 237,3 k € | +17.2% | 202,4 k € | +88.3% | 107,5 k € | +54.3% | 69,7 k € | +196% | -72,3 k € | -11.0% | -65,2 k € | -229% | 50,4 k € | -40.0% | 84 k € | -12.2% | 95,6 k € | +23.6% | 77,3 k € |
| Operating result | 359,6 k € | -11.4% | 405,8 k € | +20.5% | 336,8 k € | -6.7% | 360,8 k € | -1.0% | 364,5 k € | -9.0% | 400,4 k € | +74.8% | 229,1 k € | -22.6% | 296 k € | +16.3% | 254,5 k € | -12.5% | 290,9 k € | +30.9% | 222,3 k € | +23.5% | 179,9 k € | +112% | 84,9 k € | +184% | 29,9 k € | +126% | -115,4 k € | -10.0% | -104,8 k € | -874% | 13,5 k € | -64.7% | 38,4 k € | -23.1% | 49,9 k € | +62.6% | 30,7 k € |
| Net result | 362,6 k € | -8.4% | 395,9 k € | +18.0% | 335,6 k € | -7.2% | 361,7 k € | -1.1% | 365,8 k € | -8.9% | 401,4 k € | +75.1% | 229,2 k € | -22.6% | 296 k € | +16.2% | 254,7 k € | -10.8% | 285,5 k € | +24.5% | 229,3 k € | +23.4% | 185,8 k € | +86.1% | 99,8 k € | +105% | 48,7 k € | -82.1% | 272,2 k € | +6555% | -4,2 k € | -117% | 24,8 k € | -52.0% | 51,8 k € | -9.2% | 57 k € | +41.9% | 40,2 k € |
| Balance sheet | |||||||||||||||||||||||||||||||||||||||
| Equity | 470,1 k € | +1.6% | 462,6 k € | +1.3% | 456,6 k € | +0.1% | 456 k € | +0.4% | 454,3 k € | +1.3% | 448,5 k € | +0.3% | 447,1 k € | -0.2% | 447,9 k € | +1.4% | 441,9 k € | +1.1% | 437,2 k € | +3.7% | 421,7 k € | -7.5% | 455,8 k € | -69.0% | 1,5 M € | +7.3% | 1,4 M € | +1.2% | 1,4 M € | +20.7% | 1,1 M € | -0.4% | 1,1 M € | +2.3% | 1,1 M € | +4.9% | 1 M € | +5.7% | 991,9 k € |
| Total assets | 838,4 k € | +14.8% | 730,5 k € | -1.9% | 744,9 k € | -2.3% | 762,1 k € | -0.0% | 762,1 k € | +10.6% | 689,3 k € | -6.5% | 737,6 k € | -3.0% | 760,7 k € | +11.0% | 685,4 k € | -6.5% | 732,7 k € | -9.6% | 810,9 k € | -56.5% | 1,9 M € | +15.6% | 1,6 M € | +3.3% | 1,6 M € | +0.8% | 1,5 M € | +17.7% | 1,3 M € | +3.1% | 1,3 M € | -6.3% | 1,4 M € | +7.5% | 1,3 M € | +0.9% | 1,3 M € |
| Cash | 106,1 k € | +853% | 11,1 k € | -82.6% | 64 k € | -30.8% | 92,5 k € | -6.6% | 99 k € | +5.4% | 93,9 k € | -32.8% | 139,8 k € | +15.0% | 121,6 k € | +116% | 56,2 k € | -57.9% | 133,6 k € | -25.1% | 178,4 k € | +511% | 29,2 k € | -94.6% | 539 k € | +169% | 200,2 k € | -51.2% | 409,9 k € | +2.8% | 398,9 k € | +100% | 199,3 k € | -24.0% | 262,4 k € | +52.4% | 172,1 k € | +37.1% | 125,6 k € |
| Debts | 368,3 k € | +37.5% | 267,9 k € | -7.1% | 288,3 k € | -5.8% | 306,1 k € | -0.6% | 307,9 k € | +27.8% | 240,8 k € | -17.1% | 290,5 k € | -7.1% | 312,8 k € | +28.5% | 243,4 k € | -17.6% | 295,5 k € | -24.1% | 389,1 k € | -72.4% | 1,4 M € | +1028% | 125 k € | -26.7% | 170,4 k € | -3.5% | 176,7 k € | +1.7% | 173,7 k € | +34.3% | 129,3 k € | -46.1% | 239,8 k € | +21.3% | 197,8 k € | -17.7% | 240,3 k € |
| Other | |||||||||||||||||||||||||||||||||||||||
| Workforce | 2,6 ETP | +8.3% | 2,4 ETP | -14.3% | 2,8 ETP | -3.4% | 2,9 ETP | -3.3% | 3,0 ETP | -11.8% | 3,4 ETP | -2.9% | 3,5 ETP | +9.4% | 3,2 ETP | -5.9% | 3,4 ETP | -20.9% | 4,3 ETP | +4.9% | 4,1 ETP | 0.0% | 4,1 ETP | +7.9% | 3,8 ETP | -2.6% | 3,9 ETP | -15.2% | 4,6 ETP | +9.5% | 4,2 ETP | 0.0% | 4,2 ETP | -4.5% | 4,4 ETP | +15.8% | 3,8 ETP | -9.5% | 4,2 ETP |
Indicative valuation
As an indication, this company is worth
Board of directors
Seen on filing of 31/12/2025 · 1 active · 24 ended
Other companies at this address
| Company | CBE no. |
|---|---|
Christine Van Laer● Active | 1033.867.372 |
GLOPHARMA● Active | 0819.017.223 |
Financials
Full financial information
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 18/06/2026 | 18/07/2025 | 30/09/2024 | 26/06/2023 | 24/06/2022 | 25/06/2021 |
| General meeting | 10/06/2026 | 03/05/2025 | 04/05/2024 | 06/05/2023 | 07/05/2022 | 03/05/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Looking for more information about this company?
Try for 7 daysAnnual accounts filings
21 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2025 | 10/06/2026 | 18/06/2026 | Dutch | |
| Abridged model | 31/12/2024 | 03/05/2025 | 18/07/2025 | Dutch | |
| Abridged modelCorrection | 31/12/2023 | 04/05/2024 | 30/09/2024 | Dutch | |
| Abridged model | 31/12/2023 | 04/05/2024 | 22/08/2024 | Dutch | |
| Abridged model | 31/12/2022 | 06/05/2023 | 26/06/2023 | Dutch | |
| Abridged model | 31/12/2021 | 07/05/2022 | 24/06/2022 | Dutch | |
| Abridged model | 31/12/2020 | 03/05/2021 | 25/06/2021 | Dutch | |
| Abridged model | 31/12/2019 | 02/05/2020 | 29/06/2020 | Dutch | |
| Abridged model | 31/12/2018 | 04/05/2019 | 24/06/2019 | Dutch | |
| Abridged model | 31/12/2017 | 05/05/2018 | 28/06/2018 | Dutch | |
| Abridged model | 31/12/2016 | 06/05/2017 | 28/07/2017 | Dutch | |
| Abridged model | 31/12/2015 | 07/05/2016 | 10/06/2016 | Dutch | |
| Abridged model | 31/12/2014 | 22/04/2015 | 30/07/2015 | Dutch | |
| Abridged model | 31/12/2013 | 03/05/2014 | 28/08/2014 | Dutch | |
| Abridged model | 31/12/2012 | 04/05/2013 | 30/05/2013 | Dutch | |
| Abridged model | 31/12/2011 | 05/05/2012 | 04/06/2012 | Dutch | |
| Abridged model | 31/12/2010 | 07/05/2011 | 26/05/2011 | Dutch | |
| Abridged model | 31/12/2009 | 03/05/2010 | 07/05/2010 | Dutch | |
| Abridged model | 31/12/2008 | 02/05/2009 | 28/05/2009 | Dutch | |
| Abridged model | 31/12/2007 | 03/05/2008 | 16/05/2008 | Dutch | |
| Abridged model | 31/12/2006 | 05/05/2007 | 21/05/2007 | Dutch |
Valuation
Indicative valuation
As an indication, this company is worth
between 1 M€ and 2,5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Seen on filing of 31/12/2025 · 1 active · 24 ended
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
- Mandates09/06/2023STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - WIJZIGING RECHTSVORM - ONTSLAGEN - BENOEMINGEN
- Mandates09/06/2015ONTSLAGEN - BENOEMINGEN
- Mandates21/04/2015BENAMING - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - WIJZIGING RECHTSVORM
- Mandates09/04/2015ONTSLAGEN - BENOEMINGEN
- Mandates12/02/2015ONTSLAGEN - BENOEMINGEN
- Mandates04/02/2014ONTSLAGEN - BENOEMINGEN
- Mandates20/06/2011ONTSLAGEN - BENOEMINGEN
- Capital / shares21/10/2005KAPITAAL - AANDELEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
Source: Belgian Official Gazette
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025362,6 k €↓
- 2024Annual accounts 2024395,9 k €↑
- 2023Annual accounts 2023335,6 k €↓
- 2022Annual accounts 2022361,7 k €↓
- 2021Annual accounts 2021365,8 k €↓
- 2020Annual accounts 2020401,4 k €↑
- 2019Annual accounts 2019229,2 k €↓
- 2018Annual accounts 2018296 k €↑
- 2017Annual accounts 2017254,7 k €↓
- 2016Annual accounts 2016285,5 k €↑
- 2015Annual accounts 2015229,3 k €↑
- 2014Annual accounts 2014185,8 k €↑
- 2014Name changeAPOTHEEK GLORIEUX
- 2013Annual accounts 201399,8 k €↑
- 2012Annual accounts 201248,7 k €↓
- 2011Annual accounts 2011272,2 k €↑
- 2010Annual accounts 2010-4,2 k €↓
- 2009Annual accounts 200924,8 k €↓
- 2008Annual accounts 200851,8 k €↓
- 2007Annual accounts 200757 k €↑
- 2006Annual accounts 200640,2 k €
- 2006Name changeAPOTHEEK WINDELS
- 03/01/1980IncorporationPrivate limited company